BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA

Patent Number: TW-202345905-A

Publication Year: 2023

Application Year: 2023

Priority Year: 2022

Jurisdictions: TW

Status: N/A

Inventors:

CHIU CHRISTOPHER W L CHIU CHRISTOPHER W L CHIU CHRISTOPHER W L DINH MINH H STIRNER MARIANA C STIRNER MARIANA COTA DINH MINH H DINH MINH H STIRNER MARIANA C SZAFER-GLUSMAN IIIANA EDITH SZAFER-GLUSMAN ILIANA E SZAFER-GLUSMAN ILIANA E

Applicants:

  1. Genmab (Denmark)
    2. [NORA names: Genmab; Private Research; Denmark; Europe, EU; Nordic; OECD]

Abstract

Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone).

Patent Family Records (3)

BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA  

GENMAB AS, Genmab (Denmark) CHIU CHRISTOPHER W L, STIRNER MARIANA C, DINH MINH H, (...more)

2023, WO-2023144306-A1

BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA  

Genmab (Denmark), Genmab AS CHIU CHRISTOPHER W L, STIRNER MARIANA COTA, DINH MINH H, (...more)

2023, US-20230303693-A1

BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA

GENMAB AS, Genmab (Denmark) CHIU CHRISTOPHER W L, DINH MINH H, STIRNER MARIANA C, (...more)

2023, TW-202345905-A

Data Provider: Digital Science

LINKS
+

External Systems

SUBJECTS
+

PATENT CATEGORIES
+

METRICS
+

Citation Metrics

Times Cited in Patents: 0external link

References to Patents: [No Data Available]

References to Publications: 0external link